{"id":33227,"date":"2025-05-12T11:08:18","date_gmt":"2025-05-12T09:08:18","guid":{"rendered":"https:\/\/ggba.swiss\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/"},"modified":"2025-05-12T11:10:39","modified_gmt":"2025-05-12T09:10:39","slug":"haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/","title":{"rendered":"HAYA Therapeutics l\u00e8ve USD 65 millions pour d\u00e9velopper des th\u00e9rapies pour le traitement des maladies chroniques"},"content":{"rendered":"\n<p>Ce tour de table, co-dirig\u00e9 par <a href=\"https:\/\/sofinnovapartners.com\/\">Sofinnova Partners<\/a> et <a href=\"https:\/\/earlybird.com\/\">Earlybird Venture Capital<\/a>, comprend la participation d&rsquo;<a href=\"https:\/\/www.lilly.com\/\">Eli Lilly and Company<\/a>, d&rsquo;<a href=\"https:\/\/www.athos-cap.com\/\">ATHOS<\/a>, de <a href=\"https:\/\/nd.capital\/\">+ND Capital<\/a>, d&rsquo;<a href=\"https:\/\/www.are.com\/venture-investments.html\">Alexandria Venture Investments<\/a> et de <a href=\"https:\/\/lifelinkventures.com\/\">LifeLink Ventures<\/a>, aux c\u00f4t\u00e9s des investisseurs existants <a href=\"https:\/\/www.apollo.vc\/\">Apollo Health Ventures<\/a>, <a href=\"https:\/\/broadviewventures.org\/longview-ventures\/\">Longview Ventures<\/a>, <a href=\"https:\/\/4seeventures.ch\/\">4see ventures<\/a>, <a href=\"https:\/\/www.berninabioinvest.com\/\">BERNINA Bioinvest<\/a> et <a href=\"https:\/\/www.schroderscapital.com\/en\/global\/professional\/\">Schroders Capital<\/a>.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.hayatx.com\/\">HAYA Therapeutics<\/a> utilisera ces nouveaux capitaux pour lancer des essais cliniques sur son principal candidat, HTX-001, un traitement innovant ciblant les ARN non codants longs (lncRNA) pour le traitement de l&rsquo;insuffisance cardiaque. La premi\u00e8re indication est la cardiomyopathie hypertrophique non obstructive (nHCM), une maladie pour laquelle les options th\u00e9rapeutiques sont limit\u00e9es. En parall\u00e8le, la soci\u00e9t\u00e9 continuera \u00e0 d\u00e9velopper sa plateforme et son pipeline propri\u00e9taires, ciblant des maladies telles que la fibrose pulmonaire, l&rsquo;ob\u00e9sit\u00e9 et d&rsquo;autres affections chroniques et li\u00e9es \u00e0 l&rsquo;\u00e2ge.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Une plateforme de nouvelle g\u00e9n\u00e9ration pour d\u00e9coder le g\u00e9nome obscur<\/h4>\n\n\n\n<p>L&rsquo;approche de HAYA se concentre sur le g\u00e9nome r\u00e9gulateur, c&rsquo;est-\u00e0-dire les 98% de l&rsquo;ADN qui ne codent pas pour des prot\u00e9ines mais contr\u00f4lent l&rsquo;expression des g\u00e8nes et l&rsquo;identit\u00e9 cellulaire. La soci\u00e9t\u00e9 a constitu\u00e9 un atlas complet de ce \u00ab <a href=\"https:\/\/www.bbc.com\/future\/article\/20230412-the-mystery-of-the-human-genomes-dark-matter\">g\u00e9nome obscur<\/a> \u00bb \u00e0 l&rsquo;aide de la g\u00e9nomique multimodale, de l&rsquo;apprentissage automatique et de la biologie computationnelle afin de cartographier et de moduler les \u00e9tats cellulaires \u00e0 l&rsquo;origine des maladies.<\/p>\n\n\n\n<p>En ciblant des lncRNA sp\u00e9cifiques \u00e0 certains tissus et \u00e9tats pathologiques, HAYA vise \u00e0 reprogrammer les cellules pathologiques \u00e0 la source, offrant ainsi des th\u00e9rapies plus pr\u00e9cises et avec moins d&rsquo;effets secondaires que les approches traditionnelles. Les th\u00e9rapies guid\u00e9es par l&rsquo;ARN de la soci\u00e9t\u00e9 sont con\u00e7ues pour \u00eatre \u00e9volutives, rapides \u00e0 d\u00e9velopper et hautement programmables.<\/p>\n\n\n\n<p>Le r\u00e9cent <a href=\"https:\/\/ggba.swiss\/fr\/haya-therapteutics-conclut-une-collaboration-majeure-de-usd-1-milliard-avec-eli-lilly\/\">partenariat de HAYA avec Eli Lilly<\/a>, l&rsquo;une des plus grandes collaborations dans le domaine de la g\u00e9nomique r\u00e9glementaire, confirme encore le potentiel de sa plateforme.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HAYA Therapeutics a cl\u00f4tur\u00e9 un tour de table de s\u00e9rie A de USD 65 millions afin d&rsquo;acc\u00e9l\u00e9rer le d\u00e9veloppement clinique de ses th\u00e9rapies guid\u00e9es par l&rsquo;ARN et d&rsquo;\u00e9tendre sa plateforme g\u00e9nomique r\u00e9glementaire.<\/p>\n","protected":false},"author":6,"featured_media":33224,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1188,1140,1171,1142],"class_list":["post-33227","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-oncology-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HAYA Therapeutics l\u00e8ve USD 65 millions | GGBa<\/title>\n<meta name=\"description\" content=\"HAYA Therapeutics a lev\u00e9 USD 65 millions afin d&#039;acc\u00e9l\u00e9rer le d\u00e9veloppement clinique de ses th\u00e9rapies guid\u00e9es par l&#039;ARN.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HAYA Therapeutics l\u00e8ve USD 65 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"HAYA Therapeutics a lev\u00e9 USD 65 millions afin d&#039;acc\u00e9l\u00e9rer le d\u00e9veloppement clinique de ses th\u00e9rapies guid\u00e9es par l&#039;ARN.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-12T09:08:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T09:10:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"HAYA Therapeutics l\u00e8ve USD 65 millions pour d\u00e9velopper des th\u00e9rapies pour le traitement des maladies chroniques\",\"datePublished\":\"2025-05-12T09:08:18+00:00\",\"dateModified\":\"2025-05-12T09:10:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/\"},\"wordCount\":349,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Oncology\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/\",\"name\":\"HAYA Therapeutics l\u00e8ve USD 65 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\",\"datePublished\":\"2025-05-12T09:08:18+00:00\",\"dateModified\":\"2025-05-12T09:10:39+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"HAYA Therapeutics a lev\u00e9 USD 65 millions afin d'acc\u00e9l\u00e9rer le d\u00e9veloppement clinique de ses th\u00e9rapies guid\u00e9es par l'ARN.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Les cofondateurs de la soci\u00e9t\u00e9, Samir Ounzain, CEO, et Daniel Blessing, CTO, ont re\u00e7u un prix lors du Festival of the Future \u00e0 Munich. | \u00a9 HAYA Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HAYA Therapeutics l\u00e8ve USD 65 millions pour d\u00e9velopper des th\u00e9rapies pour le traitement des maladies chroniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HAYA Therapeutics l\u00e8ve USD 65 millions | GGBa","description":"HAYA Therapeutics a lev\u00e9 USD 65 millions afin d'acc\u00e9l\u00e9rer le d\u00e9veloppement clinique de ses th\u00e9rapies guid\u00e9es par l'ARN.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/","og_locale":"fr_FR","og_type":"article","og_title":"HAYA Therapeutics l\u00e8ve USD 65 millions | GGBa","og_description":"HAYA Therapeutics a lev\u00e9 USD 65 millions afin d'acc\u00e9l\u00e9rer le d\u00e9veloppement clinique de ses th\u00e9rapies guid\u00e9es par l'ARN.","og_url":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-05-12T09:08:18+00:00","article_modified_time":"2025-05-12T09:10:39+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"HAYA Therapeutics l\u00e8ve USD 65 millions pour d\u00e9velopper des th\u00e9rapies pour le traitement des maladies chroniques","datePublished":"2025-05-12T09:08:18+00:00","dateModified":"2025-05-12T09:10:39+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/"},"wordCount":349,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","keywords":["Biotech","Financing","Healthcare","Oncology","Pharma","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/","url":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/","name":"HAYA Therapeutics l\u00e8ve USD 65 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","datePublished":"2025-05-12T09:08:18+00:00","dateModified":"2025-05-12T09:10:39+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"HAYA Therapeutics a lev\u00e9 USD 65 millions afin d'acc\u00e9l\u00e9rer le d\u00e9veloppement clinique de ses th\u00e9rapies guid\u00e9es par l'ARN.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","width":1180,"height":811,"caption":"Les cofondateurs de la soci\u00e9t\u00e9, Samir Ounzain, CEO, et Daniel Blessing, CTO, ont re\u00e7u un prix lors du Festival of the Future \u00e0 Munich. | \u00a9 HAYA Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/haya-therapeutics-leve-usd-65-millions-pour-developper-des-therapies-pour-le-traitement-des-maladies-chroniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"HAYA Therapeutics l\u00e8ve USD 65 millions pour d\u00e9velopper des th\u00e9rapies pour le traitement des maladies chroniques"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=33227"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33227\/revisions"}],"predecessor-version":[{"id":33229,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33227\/revisions\/33229"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/33224"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=33227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=33227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=33227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}